We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+35.04%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$1.94B
AUM Growth
+$181M
Cap. Flow
+$126M
Cap. Flow %
6.49%
Top 10 Hldgs %
41.59%
Holding
123
New
29
Increased
30
Reduced
25
Closed
18

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$28.3M
2
ANAB icon
AnaptysBio
ANAB
+$26.6M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$20.4M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$19.6M
5
ERAS icon
Erasca
ERAS
+$17.1M

Top Sells

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$58.6M
2
WVE icon
Wave Life Sciences
WVE
+$16.9M
3
CGEM icon
Cullinan Oncology
CGEM
+$14.8M
4
ACLX
Arcellx
ACLX
+$14.2M
5
BBIO icon
BridgeBio Pharma
BBIO
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85.51%
2 Miscellaneous 13.84%
3 Financials 0.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADGM
101
Adagio Medical Holdings
ADGM
$11.3M
$92K ﹤0.01%
80,000
– –
RCKTW icon
102
Rocket Pharmaceuticals Warrant
RCKTW
$74.7K
$1.18K ﹤0.01%
75,000
– –
ABUS icon
103
CALL
Arbutus Biopharma
ABUS
$1B
– –
-521,900
Closed -$2.51M
AMGN icon
104
CALL
Amgen
AMGN
$234B
– –
-135,000
Closed -$44.2M
AMGN icon
105
Amgen
AMGN
$234B
– –
-10,000
Closed -$3.27M
AVDL
106
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-250,000
Closed -$5.39M
FBRX icon
107
CALL
Forte Biosciences
FBRX
– –
-22,400
Closed -$611K
GERN icon
108
Geron
GERN
$970M
– –
-1,500,000
Closed -$1.98M
IBB icon
109
CALL
iShares Biotechnology ETF
IBB
$10.5B
– –
-400,000
Closed -$67.5M
MRSN
110
DELISTED
Mersana Therapeutics
MRSN
– –
-100,000
Closed -$2.89M
QURE icon
111
uniQure
QURE
$3.38B
– –
-50,000
Closed -$1.01M
RARE icon
112
Ultragenyx Pharmaceutical
RARE
$2.52B
– –
-75,000
Closed -$1.73M
RCUS icon
113
Arcus Biosciences
RCUS
$3.72B
– –
-300,000
Closed -$7.15M
SMMT icon
114
PUT
Summit Therapeutics
SMMT
$11B
– –
-350,000
Closed -$6.12M
TNGX icon
115
Tango Therapeutics
TNGX
$3.94B
– –
-1,000,000
Closed -$8.86M
VTYX
116
DELISTED
Ventyx Biosciences
VTYX
– –
-6,484,558
Closed -$58.6M
XBI icon
117
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.3B
– –
-1,500,000
Closed -$183M
XLV icon
118
CALL
State Street Health Care Select Sector SPDR ETF
XLV
$44.5B
– –
-250,000
Closed -$38.7M
LENZ
119
PUT
LENZ Therapeutics
LENZ
$161M
– –
-100,000
Closed -$1.6M
PCSC
120
DELISTED
Perceptive Capital Solutions
PCSC
– –
-50,000
Closed -$652K
1 2 3 4
5

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Affinity Asset Advisors held 123 positions worth $1.94B, up 10% from $1.76B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Affinity Asset Advisors deployed $126M of net new capital in Q1 2026, opening 29 new positions and adding to 30 existing holdings. Its largest new stake was Enliven Therapeutics: 586,904 shares worth $23M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 77% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Wave Life Sciences, an estimated $16.9M trimmed.

  • Affinity Asset Advisors's largest Q1 2026 buy was Enliven Therapeutics: 586,904 shares worth $23M.
  • Affinity Asset Advisors added most to Roivant Sciences in Q1 2026, an estimated $28.3M increase.
  • Affinity Asset Advisors's biggest Q1 2026 reduction was Wave Life Sciences, cutting an estimated $16.9M.
  • Affinity Asset Advisors fully exited Ventyx Biosciences in Q1 2026, selling an estimated $58.6M.
  • Affinity Asset Advisors's ten largest holdings make up 42% of its $1.94B portfolio in Q1 2026.
  • Affinity Asset Advisors opened 29 new positions and closed 18 in Q1 2026.
  • Affinity Asset Advisors's portfolio value rose 10% quarter-over-quarter to $1.94B.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.